Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Is Radiation Therapy Safe? Experts Break Down the Pros and Cons(File Photo) Radiation therapy kills cancer cells ... t become radioactive. In comparison, internal radiation therapy may cause the ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

Increasingly, full-body computed tomography screening is being marketed to healthy people. In discussions of the pros and cons of this procedure, potential risks from radiation exposure frequently ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

Jan. 27, 2025 — Basal cell ... Your Skin and Cools You Off, Too Dec. 19, 2024 — Wearing sunscreen is important to protect your skin from the harmful effects of UV radiation but doesn't cool ...

How can doctors assess whether a treatment is ineffective? In an interview with HT Lifestyle, Dr Anjali Kulkarni, Vice President - RWE Strategy and Analytics and Oncologist at 4baseCare ...

Skin tags are benign growths that can pop up in a few areas around the body ... t covered by health insurance, says Goldbach. This is because it’s usually considered to be a cosmetic treatment.

Novartis' CAR-T Kymriah has become the first therapy ... follicular lymphoma use last year as well, a little after Yescarta, adding to its earlier approvals for diffuse large B-cell lymphoma ...